Randomized Study of Aspirin Resistant Patients Undergoing Angioplasty
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00289601|
Recruitment Status : Terminated (Sponsor support withdrawn)
First Posted : February 10, 2006
Last Update Posted : July 20, 2007
|Condition or disease||Intervention/treatment||Phase|
|Angioplasty||Drug: eptifibatide||Phase 4|
The primary objective of this study is to determine if the use of eptifibatide is associated with a significant difference in post-PCI myonecrosis (measured as an elevation of CK-MB ratio ≥ 2 times upper limit of normal [ULN]) within 24 hours of low-medium risk PCI in patients who are aspirin or clopidogrel non-responsive as determined by VerifyNow Aspirin and P2Y12 testing.
Secondary study objectives will include an assessment of safety. These safety determinations will be determined by monitoring the rates of MACE (defined as death, MI, ischemic [non-hemorrhagic] stroke and urgent revascularization by repeat PCI or CABG), bleeding events, rate of bailout procedures performed, elevations of CK-MB ratio (in the range of 3 to 5 times ULN and greater than 5 times ULN) and elevations of troponin I.
This study is a randomized, double-blind, multi-center study designed to compare differences in rates of myonecrosis (measured as an elevation of CK-MB ratio ≥ 2 times ULN) within 24 hours following low-medium risk percutaneous coronary intervention (PCI) in aspirin or clopidogrel non-responsive patients who are randomized to heparin with or without eptifibatide therapy during PCI. All subjects must also be pretreated with clopidogrel (300-600 mg) at least 2 hours before PCI. Study subjects will be randomized to either eptifibatide and unfractionated heparin or unfractionated heparin and placebo. Study subject randomization in aspirin non-responsive patients will be stratified based upon clopidogrel responsiveness.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||1200 participants|
|Intervention Model:||Single Group Assignment|
|Official Title:||Research Evaluation to Study Individuals Who Show Thromboxane Or P2Y12 Receptor Resistance|
|Study Start Date :||March 2006|
|Estimated Study Completion Date :||December 2007|
- The primary endpoint is the incidence of myonecrosis, defined as an elevation in creatinine kinase – myocardial band (CK-MB) > 2 x IU/ml above the institution’s upper limit of normal within 24 hours following low-medium risk PCI.
- Incidence of CK-MB elevation >3x ULN
- Incidence of CK-MB elevation to 3-5x ULN
- Incidence of CK-MB elevation >5x ULN
- Incidence of troponin I > 0.1ng/ml
- MACE rates reported at discharge, 30 days and 6 months. (MACE is defined as a composite endpoint of death, MI, ischemic (non-hemorrhagic) stroke, and urgent target vessel revascularization)
- Rate of bail-out use of eptifibatide/placebo.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00289601
|United States, Massachusetts|
|Brigham and Women's Hospital|
|Boston, Massachusetts, United States, 02115|
|Principal Investigator:||Daniel I Simon, MD||University Hospitals Cleveland Medical Center|